New combo attack on liver tumors shows promise for Tough-to-Treat cancer

NCT ID NCT06071052

Completed Disease control Sponsor: First Affiliated Hospital, Sun Yat-Sen University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a three-part treatment for people with colorectal cancer that spread to the liver and stopped responding to standard treatments. The approach combines two minimally invasive procedures (TACE and HAIC) with the targeted drug regorafenib. The goal was to see if this combination could shrink tumors and improve survival in 21 patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: regorafenib
What this could lead to: If this works, it could offer a new treatment option for people with colorectal cancer that has spread to the liver and hasn't responded to standard therapies.
What could go wrong: This is a small, early-phase study with only 21 participants, so results may not apply to everyone. The combination also carries risks like liver damage or side effects from the drugs and procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER WITH LIVER METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal carcinoma malignant colon neoplasm metastasis from malignant tumor of colon

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER METASTASIS COLON CANCER

Contacts and locations

Locations

the first affiliated hospital, Sun-Yat sen university

Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.